Koren, Yangzijiang, Zhengda sunny! Three over 1 billion injections have been evaluated

Medicine Network November 26th, November 25th, NMPA official website updated the latest approved drug information, Sichuan Colum Pharmaceuticals' cytosine injection, Yangzijiang Pharmaceutical Group's iodized kesal injection, Nanjing Zhengda Tianqing Pharmaceutical injection of sodium totralatone, the three injections of consistent evaluation of supplementary applications were officially approved.
55 injections have so far been evaluated consistently in 10 major categories, according to the U.S. Internal Network.
Figure 1: Approved information sources of the three major injections: NMPA official website Figure 2: Sales of pyrethroid injections Source: Minet China's public medical institutions end-competitive pattern of pyrethroid injections for the treatment of malignant tumors caused by hypercalcemia, and joint standard anti-tumor drugs for the treatment of solid tumor bone metastasis patients and multiple myeloma patients bone damage.
The relevant products on the market at present include injection of pyrethroid acid, injection of pyrethroid acid thick solution and pyrethroid injection, the variety in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) terminal sales peaked in 2018, exceeding the 2 billion mark.
Sichuan Colum Pharmaceuticals was first approved for the market in 2018 with a 100 ml: 5 mg (by C5H10N2O7P2), registered as the original chemical class 6; 202 In January 0, the company's pyrethroid acid injection another specification 100ml: 4mg (according to C5H10N2O7P2) according to the 3 types of imitation declaration was approved and treated as a review, Koren took the first evaluation of the species.
The acceptance number of this review, the corresponding large probability is the specification of 100ml: 5mg (according to C5H10N2O7P2) products, that is, the two specifications of Koren's pyrethroid injections have been evaluated.
year, 7 injections have been evaluated/treated by Koren and his subsidiaries.
Figure 3: Sales of iodized kesha alcohol injections Source: Minet China's public medical institutions terminal competition pattern iodized kesal injections are TOP1 varieties of shadow agents, in 2019 in China's public medical institutions terminal sales of nearly 3.7 billion yuan.
the first half of 2020, the market share of jiangsu Hengrui Pharmaceuticals, the leading company, reached 53.01%, and the share of Yangzijiang Pharmaceutical Group rose to 12.61%.
In August 2020, Shanghai Staili Pharmaceutical's four types of imitation listing applications were approved and evaluated, becoming the product's first over-evaluation enterprises, this Yangzijiang consistency evaluation supplementary application was approved, becoming the product's second over-evaluation enterprise.
year, Yangzijiang and its subsidiaries have reviewed / treated the same injection products have 5.
figure 4: Sales of pythola injection Source: Minet China's public medical institutions terminal competition pattern of the current market for the injection of sodium diazepam, suitable for diphthal ulcers, stomach ulcers, acute gastric mucosal lesions, compound stomach ulcers and other acute upper gastrointestinal bleeding.
The product peaked in 2016 at nearly 8.8 billion yuan in China's public medical institutions, falling back to 6.7 billion yuan in 2019, leading Yangzijiang Pharmaceutical Group's market share of 28.07 percent in the first half of 2020, and Nanjing Zhengda Tianqing Pharmaceuticals' share of less than 1 percent.
In November 2020, Jiangsu Osaikang Pharmaceuticals, Yangzijiang Pharmaceutical Group, Hangzhou Sino-American East China Pharmaceuticals were approved for the consistent evaluation of supplementary applications, this Time Nanjing Zhengda Tianqing Pharmaceuticals was approved to become the fourth enterprise to evaluate the product.
, Nanjing Zhengda Tianqing Pharmaceutical (excluding subsidiaries) has been evaluated / treated as the same injection has 4.
Figure 5: Distribution of injections that have been reviewed/reviewed Source: Minet MED2.0 China Drug Review Database Minet data show that as of November 25, 2020, it has been reviewed There were 55 injectable products, more than 10 over-rated injections of nervous system drugs, anti-tumor and immunomodulants, and only 1 injectable of hormone-based preparations (without sex hormones) and cardiovascular drugs.
source: NMPA official website, MiNet database